# Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

> **NCT05278975** · PHASE1,PHASE2 · UNKNOWN · sponsor: **RS Oncology LLC** · enrollment: 186 (estimated)

## Conditions studied

- Malignant Pleural Effusion
- Malignant Pleural Mesothelioma
- Mesothelioma
- Mesotheliomas Pleural
- Mesothelioma; Lung
- Pleural Effusion, Malignant

## Interventions

- **DRUG:** RSO-021

## Key facts

- **NCT ID:** NCT05278975
- **Lead sponsor:** RS Oncology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-31
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05278975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05278975, "Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05278975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*